Mara Ghilardi

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials

Fausto Petrelli, Karen Borgonovo, Mary Cabiddu et al. · Journal of Gastrointestinal Oncology · 2017 · 69 citations · Full text

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study

Anna Falanga, Armando Santoro, Roberto Labianca et al. · Thrombosis Research · 2016 · 34 citations

Risk Assessment, Oncology, Cardiovascular Disease +13

Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort

Cristina Verzeroli, Cinzia Giaccherini, Laura Russo et al. · Journal of Thrombosis and Haemostasis · 2023 · 28 citations · Full text

Thrombin generation predicts early recurrence in breast cancer patients

Marina Marchetti, Cinzia Giaccherini, Giovanna Masci et al. · Journal of Thrombosis and Haemostasis · 2020 · 26 citations · Full text

Thrombosis, Breast Oncology, Medicine +5